neutral
Recently
Corona Remedies delivers strong listing pop as investor demand stays elevated
Corona Remedies listed at a sharp premium after strong IPO demand, as investors backed its profitable growth profile, high return ratios, and leadership in key pharmaceutical therapy areas.
Corona Remedies made a strong debut on Dalal Street, listing at a 38.42 percent premium over its IPO price of ₹1,062 and trading above ₹1,470 on both NSE and BSE during early hours. The ₹655 crore offer for sale issue saw heavy oversubscription across investor categories, reflecting confidence in the company’s steady profitability, strong return ratios, and focused presence in chronic therapy segments.